West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack

Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products

EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced participation at Pharmapack 2026 in Paris, France to showcase its leadership and expertise on industry challenges and trends in packaging and containment. This event marks the global commercial availability of West Synchrony™ S1 prefillable syringe (PFS) system.

West Synchrony S1 PFS system provides a broad product portfolio including 1 ml long and 2.25 ml staked needle options for biologics and 1 ml standard staked needle and Luer lock options for vaccines. Staked needle system options come with either a rigid or soft needle shield and Luer lock system options will have an integrated tip cap. The system also includes high performance West NovaPure® and FluroTec™ barrier film plungers.

"As a market leader, West closely monitors shifts in the global drug pipeline by emerging companies, particularly the growing demand for combination products alongside the movement of care from hospital to home, both of which introduce new complexity into regulatory and development processes," Stacey Vaughan, Vice President, Marketing and Portfolio Management at West. "This surge of innovation across the industry further highlights why now is the right time to introduce West Synchrony S1 prefillable syringe system."

In addition, West will highlight its industry expertise through learning labs and a product gallery:

• Stop Piecing It Together—Get an Integrated Verified Prefillable Syringe System from One Source- Wednesday, January 21, 11:30 a.m.- 12:00 p.m. CET
  • Presented by Bettine Boltres Ph.D., Director of Scientific Affairs
• Product Gallery- West Synchrony S1 PFS System- Wednesday, January 21, 3:25-3:30 p.m. CET
  • Presented by Andy Polywacz, President of Integrated Systems
• Flexible Assembly and Packaging Approach for Steering Combination Products Through Clinical Trials- Thursday, January 22, 10:10- 10:40 a.m. CET
  • Presented by Richard Kieran, Director of Business Development          

For more information about West Synchrony S1 PFS system, click here.

For more information about Pharmapack, click here.

Forward-Looking Statements
Certain forward-looking statements are included in this press release. They use words such as "standard," "streamline," "accelerate," "secures," "reliable," "meets," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations.  Specifically, there is no certainty that West's introduction of the Synchrony PFS system will achieve any particular result.  These forward-looking statements involve a number of risks and uncertainties. Various factors could cause the actual results to differ materially from those expressed in, or underlying, these forward-looking statements, such as customers' changing inventory requirements and manufacturing plans; customer decisions to move forward with new products and product categories; average profitability, or mix, of the products offered for sale; dependence on third party suppliers and partners; interruptions or weaknesses in the supply chain; increased raw material costs; fluctuations in currency exchange; and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2024. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

About West   
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of lifesaving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.  

Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. 

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. 

SOURCE West Pharmaceutical Services, Inc.